BioSpace News Archive

OMass Therapeutics, a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, announces the appointment of Melissa Faris as Chief Business Officer, effective immediately.

Ionetix Corporation announced the signing of a supply agreement for the therapeutic radioisotope actinium-225 with Bayer.

Valneva SE announced the availability of documentation for its Extraordinary General Meeting which will be held on December 20, 2023 at 2:00 p.m. CET at the Radisson Blu Hotel, 6 place Aristide Briand, 44000 Nantes, France.

Cellectis anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investment Agreement with AstraZeneca regarding the contemplated additional equity investment of $140M by AstraZeneca, which was previously announced on November 1, 2023.

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference Tuesday, November 28 at 1:45 pm EST (10:45 am PST/6:45 pm GMT) and will be hosting in-person meetings with the investment community at the conference.

Tessellate BIO announces the appointment of multiple international experts to its Scientific Advisory Board.

Cardiawave SA announced the publication of results from its First-In-Human clinical studies on 40 patients suffering from CAS treated with its NIUT in The Lancet and the completion of the enrollment of 60 patients in its “Valvosoft® pivotal study”.

Arcellx, Inc. and Kite, a Gilead Company, announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.

Pharvaris today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will host a virtual KOL event on Monday, November 20, 2023 at 10:00 AM ET to discuss new Phase 2 ReSPECT-GBM data in recurrent glioblastoma presented at the Society for NeuroOncology (SNO) Conference.